Biosciences – Talk Bio

Actionable Insights Powered by AI

Junshi Biosciences Announces Phase 3 Win for IL-17A Drug JS005 in Psoriasis, Prepares China NDA Submission

2 days ago talkbio0Tagged Biosciences, China, clinical endpoints, Drug Approval, IL-17A monoclonal antibody, JS005, Junshi, Psoriasis

Junshi Biosciences; JS005; IL-17A monoclonal antibody; psoriasis; phase 3 trial; clinical endpoints; China drug approval

Enveda Raises $150M Series D, Advances Nature-Inspired Drug Programs

6 days ago talkbio0Tagged Biosciences, Dermatitis, Atopic, Enveda, Immune System Diseases, Investments, Mikael, nature-inspired drug discovery, Series D

Enveda Biosciences; Series D funding; $150 million; nature-inspired drug discovery; atopic dermatitis; immune diseases; Mikael Dolsten; biotech investment

Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics

3 months ago talkbio0Tagged ABS-0871, ABS-1230, Actio, Biosciences, Charcot-Marie-Tooth Disease, Clinical Trials, Drugs, Orphan, Epilepsy, Infrequent, Inhibitor, KCNT1 gene, Regeneron, Series B financing, TRPV4 protein, human

Regeneron; Actio Biosciences; rare diseases; Series B financing; KCNT1 inhibitor; TRPV4 inhibitor; ABS-1230; ABS-0871; Charcot-Marie-Tooth disease; epilepsy; orphan drug; clinical trials

Ascletis’ Sagimet-Sourced Oral FASN Inhibitor Achieves All Endpoints in Pivotal Acne Study

3 months ago talkbio0Tagged Acne Vulgaris, Ascletis, Biosciences, Chinese study, clinical endpoints, Clinical Trials, Denifanstat, Inhibitor, Lesion, oral FASN, Phase 3, Sagimet

Ascletis; Sagimet Biosciences; denifanstat; oral FASN inhibitor; phase 3 clinical trial; acne vulgaris; clinical endpoints; lesion reduction; Chinese study

Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures

4 months ago talkbio0Tagged Biosciences, Biotech Layoffs, Collaboration termination, Facility (object), IgM antibodies, Immunoglobulin M, Immunology, Inflammation, Neoplasms, Reparative closure, sanofi

Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology

Daiichi turns to Nosis for AI-designed RNA delivery tech

6 months ago talkbio0Tagged Biosciences, Cells, Chronic disease, Daiichi, Nosis, Partnership, RNA, Sankyo

Nosis, Daiichi, RNA, Sankyo, Partnership, Biosciences, Cells, Chronic disease

Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug

7 months ago talkbio0Tagged Arbitrating, asset, Biosciences, Clinical Trials, Failure (biologic function), Fraud, Freezing, Hypertensive disease, kilobase pairs, Nordisk, Ocedurenone

Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration

Retro Biosciences, Backed by Sam Altman, Seeks $1 Billion to Extend Human Lifespan by 10 Years

8 months ago talkbio0Tagged Altman, Artificial (qualifier value), Biosciences, Biotechnology, Dorsal, Funding, Health care facility, Homo sapiens, Intelligence, Lifespan Extension, Series

Retro Biosciences, Sam Altman, Human Lifespan Extension, Biotechnology, Series A Funding, Artificial Intelligence in Healthcare

Leo Pharma Acquires EU Rights to Loqtorzi, Boosting Marketing Efforts for PD-1 Inhibitor

8 months ago talkbio0Tagged Biosciences, EU, Inhibitor, Junshi, Loqtorzi, Nasopharyngeal carcinoma, PDCD1 gene, Pharma, rights

Loqtorzi, PD-1 Inhibitor, Nasopharyngeal Carcinoma, EU Rights, Leo Pharma, Junshi Biosciences, Marketing Efforts

IGM Biosciences Halts Autoimmune Projects Amid Layoffs Following Disappointing Trial Data

8 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, bispecific antibody T cell, engagers, IGM-2644, Immunoglobulin M, imvotamab, Industry

IGM Biosciences, layoffs, autoimmune diseases, bispecific antibody T cell engagers, imvotamab, IGM-2644, biotech industry